| MEDI-563, a humanized anti–IL-5 receptor α mAb with enhanced antibody-dependent cell-mediated cytotoxicity function R Kolbeck, A Kozhich, M Koike, L Peng, CK Andersson, MM Damschroder, ... Journal of Allergy and Clinical Immunology 125 (6), 1344-1353. e2, 2010 | 655 | 2010 |
| Modulation of the effector functions of a human IgG1 through engineering of its hinge region WF Dall’Acqua, KE Cook, MM Damschroder, RM Woods, H Wu The Journal of Immunology 177 (2), 1129-1138, 2006 | 289 | 2006 |
| Targeting CD73 in the tumor microenvironment with MEDI9447 CM Hay, E Sult, Q Huang, K Mulgrew, SR Fuhrmann, KA McGlinchey, ... Oncoimmunology 5 (8), e1208875, 2016 | 267 | 2016 |
| Humanization of antibodies H Wu, W Dall-Acqua, M Damschroder US Patent App. 10/923,068, 2005 | 251 | 2005 |
| Structural insights into neonatal Fc receptor-based recycling mechanisms V Oganesyan, MM Damschroder, KE Cook, Q Li, C Gao, H Wu, ... Journal of Biological Chemistry 289 (11), 7812-7824, 2014 | 245 | 2014 |
| Antibody humanization by framework shuffling WF Dall’Acqua, MM Damschroder, J Zhang, RM Woods, L Widjaja, J Yu, ... Methods 36 (1), 43-60, 2005 | 222 | 2005 |
| Assessment of an anti-alpha-toxin monoclonal antibody for prevention and treatment of Staphylococcus aureus-induced pneumonia L Hua, JJ Hilliard, Y Shi, C Tkaczyk, LI Cheng, X Yu, V Datta, S Ren, ... Antimicrobial agents and chemotherapy 58 (2), 1108-1117, 2014 | 189 | 2014 |
| Current approaches to fine mapping of antigen–antibody interactions WM Abbott, MM Damschroder, DC Lowe Immunology 142 (4), 526-535, 2014 | 169 | 2014 |
| B-cell depletion in vitro and in vivo with an afucosylated anti-CD19 antibody R Herbst, Y Wang, S Gallagher, N Mittereder, E Kuta, M Damschroder, ... Journal of Pharmacology and experimental therapeutics 335 (1), 213-222, 2010 | 159 | 2010 |
| Structural characterization of a human Fc fragment engineered for extended serum half-life V Oganesyan, MM Damschroder, RM Woods, KE Cook, H Wu, ... Molecular immunology 46 (8-9), 1750-1755, 2009 | 129 | 2009 |
| Direct targeting of αvβ3 integrin on tumor cells with a monoclonal antibody, Abegrin™ K Mulgrew, K Kinneer, XT Yao, BK Ward, MM Damschroder, B Walsh, ... Molecular cancer therapeutics 5 (12), 3122-3129, 2006 | 127 | 2006 |
| Molecular basis for antagonistic activity of anifrolumab, an anti-interferon–α receptor 1 antibody L Peng, V Oganesyan, H Wu, WF Dall’Acqua, MM Damschroder MAbs 7 (2), 428-439, 2015 | 116 | 2015 |
| Inhibition of CD73 AMP hydrolysis by a therapeutic antibody with a dual, non-competitive mechanism of action JC Geoghegan, G Diedrich, X Lu, K Rosenthal, KF Sachsenmeier, H Wu, ... MAbs 8 (3), 454-467, 2016 | 111 | 2016 |
| Structural characterization of a mutated, ADCC-enhanced human Fc fragment V Oganesyan, MM Damschroder, W Leach, H Wu, WF Dall’Acqua Molecular immunology 45 (7), 1872-1882, 2008 | 111 | 2008 |
| Mechanisms of neutralization of a human anti-α-toxin antibody V Oganesyan, L Peng, MM Damschroder, L Cheng, A Sadowska, ... Journal of Biological Chemistry 289 (43), 29874-29880, 2014 | 97 | 2014 |
| Humanization of antibodies H Wu, W Dall-Acqua, M Damschroder US Patent App. 10/920,899, 2005 | 91 | 2005 |
| Modulation of antibody specificity by tailoring the affinity to cognate antigens W Dall'Acqua, M Damschroder, M Kinch, K Carles-Kinch US Patent App. 11/259,133, 2006 | 75 | 2006 |
| Framework shuffling of antibodies to reduce immunogenicity and manipulate functional and biophysical properties MM Damschroder, L Widjaja, PS Gill, V Krasnoperov, W Jiang, ... Molecular Immunology 44 (11), 3049-3060, 2007 | 74 | 2007 |
| Mitigation of reversible self-association and viscosity in a human IgG1 monoclonal antibody by rational, structure-guided Fv engineering JC Geoghegan, R Fleming, M Damschroder, SM Bishop, HA Sathish, ... MAbs 8 (5), 941-950, 2016 | 66 | 2016 |
| Modulation of antibody effector function by hinge domain engineering W Dall'Acqua, H Wu, M Damschroder, J Casa-Finet US Patent 8,008,443, 2011 | 66 | 2011 |
